Nasus Pharma Ltd
NSRX5.440USD
-0.550-9.18%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
49.28MCap. mercado
PérdidaP/E TTM
Más Datos de Nasus Pharma Ltd Compañía
Nasus Pharma Ltd is an Israel-based pharmaceutical company. The Company conducts ins business activities as a pharmaceutical preparation and intranasal powder-based drug delivery systems manufacturer. Its microsphere technology enables rapid, non-invasive administration of medications for conditions such as anaphylaxis and opioid overdose among others. Nasus Pharma Ltd's formulations are designed for relatively fast absorption, ease of use, and effectiveness in critical situations (such as emergency use). The Company's products predominantly aim to improve access to life-saving treatments by allowing easy administration by caregivers or non-professionals, as well as medical doctors and emergency nurses.
Información de Nasus Pharma Ltd
Símbolo de cotizaciónNSRX
Nombre de la empresaNasus Pharma Ltd
Fecha de salida a bolsaAug 13, 2025
Director ejecutivoTeleman (Dan)
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 13
DirecciónYigal Alon 65
CiudadTEL AVIV-YAFO
Bolsa de valoresNASDAQ OMX – NASDAQ Basic Amex
PaísIsrael
Código postal- -
Teléfono97237326616
Sitio Webhttps://www.nasuspharma.com
Símbolo de cotizaciónNSRX
Fecha de salida a bolsaAug 13, 2025
Director ejecutivoTeleman (Dan)
Ejecutivos de Nasus Pharma Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Udi Gilboa
Mr. Udi Gilboa
Co-Founder, Executive Chairman of the Board of Director
Co-Founder, Executive Chairman of the Board of Director
1.90M
+55292.00%
Dr. Dalia Megiddo
Dr. Dalia Megiddo
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
1.89M
+42854.00%
Mr. Dan Teleman
Mr. Dan Teleman
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Tair Lapidot, Ph.D.
Dr. Tair Lapidot, Ph.D.
Vice President of Research and Development and Clinical Development
Vice President of Research and Development and Clinical Development
--
--
Galia Temtsin Kryaz
Galia Temtsin Kryaz
Director of CMC and Product Development
Director of CMC and Product Development
--
--
Mr. Oren Elmaliach
Mr. Oren Elmaliach
Director of Finance
Director of Finance
--
--
Mr. Ronnie Hershman
Mr. Ronnie Hershman
Independent Director
Independent Director
--
--
Mr. David Silberman, CPA
Mr. David Silberman, CPA
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Sharon Shacham, Ph.D.
Dr. Sharon Shacham, Ph.D.
Independent Director Nominee
Independent Director Nominee
--
--
Isaac Israel
Isaac Israel
Independent Director Nominee
Independent Director Nominee
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Udi Gilboa
Mr. Udi Gilboa
Co-Founder, Executive Chairman of the Board of Director
Co-Founder, Executive Chairman of the Board of Director
1.90M
+55292.00%
Dr. Dalia Megiddo
Dr. Dalia Megiddo
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
1.89M
+42854.00%
Mr. Dan Teleman
Mr. Dan Teleman
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Tair Lapidot, Ph.D.
Dr. Tair Lapidot, Ph.D.
Vice President of Research and Development and Clinical Development
Vice President of Research and Development and Clinical Development
--
--
Galia Temtsin Kryaz
Galia Temtsin Kryaz
Director of CMC and Product Development
Director of CMC and Product Development
--
--
Mr. Oren Elmaliach
Mr. Oren Elmaliach
Director of Finance
Director of Finance
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: lun., 17 de nov
Actualizado: lun., 17 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Gilboa (Udi)
21.09%
Megiddo (Dalia)
20.96%
Hershman Holdings L.L.C.
9.89%
Capital Point Ltd
6.38%
Phoenix Solutions Ltd
4.76%
Otro
36.92%
Accionistas
Accionistas
Proporción
Gilboa (Udi)
21.09%
Megiddo (Dalia)
20.96%
Hershman Holdings L.L.C.
9.89%
Capital Point Ltd
6.38%
Phoenix Solutions Ltd
4.76%
Otro
36.92%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
43.95%
Corporation
21.03%
Investment Advisor
0.03%
Otro
34.99%
Participación institucional
Actualizado: mié., 21 de ene
Actualizado: mié., 21 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q4
2
3.24K
0.00%
--
2025Q4
2
2.38K
0.03%
+1.14K
2025Q3
7
5.35M
59.33%
+5.35M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Gilboa (Udi)
1.90M
21.09%
+55.29K
+3.00%
Sep 30, 2025
Megiddo (Dalia)
1.89M
20.96%
+42.85K
+2.32%
Sep 30, 2025
Hershman Holdings L.L.C.
891.19K
9.89%
+414.18K
+86.83%
Sep 30, 2025
Capital Point Ltd
575.13K
6.38%
+575.13K
--
Aug 14, 2025
Phoenix Solutions Ltd
429.31K
4.76%
--
--
Sep 30, 2025
Krayz (Galia Temtsin)
171.72K
1.91%
+171.72K
--
Aug 12, 2025
Morgan Stanley Smith Barney LLC
2.00K
0.02%
+2.00K
--
Sep 30, 2025
UBS Financial Services, Inc.
1.24K
0.01%
+1.24K
--
Sep 30, 2025
Lapidot (Tair Ph.D.)
10.00
0%
+10.00
--
Aug 12, 2025
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
